Prostate Cancer Clinical Trial
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
Summary
This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.
Eligibility Criteria
Biochemical recurrent and pre-prostatectomy staging participants will be eligible and must meet the following criteria:
Inclusion Criteria:
Age ≥ 18 years
Histopathologically confirmed or biopsy proven prostate adenocarcinoma.
Concern for metastatic disease in one of the following settings:
Initial staging with intermediate to high risk prostate cancer.
Biochemical recurrence after initial therapy.
Ability to understand a written informed consent document, and the willingness to sign it
Exclusion Criteria:
1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Francisco California, 94143, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.